Facebook Twitter LinkedIn

Niacin 250 TR

gluten free vegetarian vegetable capsule

Time-released formula supplies 250mg of niacin over a 6-8 hour period to minimize flushing and prolong beneficial effects

  • Optimizes cardiovascular wellness
  • Maintains circulatory health
  • Supports healthy blood cholesterol levels
  • Promotes nervous system health

Discontinued Product

See Niacin 500 mg Flush Free (60 capsules) »

Product Information Sheet (PDF)

Unique Properties

Patient One Patient One Niacin 250 supplies a potent serving of niacin in an extended time-release form that gradually enters the bloodstream. Our time-release formulation supplies all of niacin’s benefits in a form that is gentle and safe. Because niacin releases histamine and causes capillary dilation which may cause a flushing of the skin, Patient One Niacin 250 is designed to maximize patient compliance by minimizing the “niacin flush."

Niacin is an evidence-backed B vitamin that is most commonly used to support cardiovascular wellness but has also shown additional benefits for circulatory wellness, blood health and nervous system health. Patient One Niacin 250 is an ideal foundation nutrient for your patients’ cardiovascular wellness and overall vitality. 

Key Ingredients

Niacin 250mg

Also known as vitamin B-3 or nicotinic acid, niacin is one of the most studied and documented nutrients for support of lipid levels already within normal range, especially high-density lipoprotein cholesterol (HDL-C). Niacin occurs in the body as two metabolically active coenzymes, NAD (nicotinaminde adenine dinucleotide) and NADP (NAD phosphate). The niacin coenzymes NAD and NADP have extensive roles in energy-related and biosynthetic metabolic processes. At least 200 enzymes depend on these niacin cofactors. The NAD-dependent enzymes are involved in mostly catabolic, oxidative reactions that release energy from carbohydrate, fat, protein and alcohol, whereas the NADP-dependent enzymes more commonly function in biosynthetic pathways of such compounds as fatty acids and steroid hormones. 

Research has suggested that aside from its functions as NAD and NADP, niacin influences pathways associated with triglycerides and HDL cholesterol, helping to maintain blood cholesterol levels that are already within normal range. Niacin has been found to modulate lipoprotein biosynthesis in the liver, inhibit the release of free fatty acids from adipocytes, inhibit synthesis of apo B, induce lipoprotein lipase, and help maintain the structure and function of HDL by reducing the amount of apo A-1 broken down from HDL during hepatic processing.(1,2)

Niacin is the only B vitamin that can be synthesized in the liver from the amino acid tryptophan. (3-5) In its coenzyme forms, niacin is crucial to energy transfer reactions, particularly the metabolism of glucose, fat, and alcohol. 6,7) Niacin’s beneficial effects on blood lipids is well-documented.(8-20)




  • In 2004, a double-blind randomized placebo-controlled study of once-daily extended-release niacin was added to background statin therapy in patients with known coronary heart disease and low levels of high-density lipoprotein cholesterol (HDL-C). The study clearly demonstrated that niacin offers targeted support of cardiovascular health and supports healthy carotid intima-media thickness. The combination of extended-release niacin to statin therapy slowed the progression of atherosclerosis among individuals with known coronary heart disease and moderately low HDL-C.(21)
  • In a meta-analysis of seven trials of secondary prevention, niacin was associated with a significant reduction in cardiovascular events and possible small but non-significant decreases in coronary and cardiovascular mortality. Compared to placebo group, niacin therapy significantly reduced coronary artery revascularization, nonfatal myocardial infarction, stroke, and TIA, as well as a possible but nonsignificant decrease in cardiac
  • mortality.(24)


  1. Morgan JM, Carey CM, Lincoff A, et al. The effects of niacin on lipoprotein subclass distribution. Prev Cardiol. 2004 Fall;7(4):182-7; quiz 188. [PMID: 8424822]
  2. Holland RE, Rahman K, Morris AI, et al. Effect of niacin on biliary lipid output in the rat. Biochem Pharmacol. 1993 Jan 7;45(1):43-49. [PMID: 8424822]
  3. Am J Clin Nutr. 1981 Mar;34(3):423-7.
  4. Am J Clin Nutr. 1980 Oct;33(10):2157-67.
  5. J Nutr. 1964 Mar;82:395-400.
  6. Mayo Clin Proc. 2008 Apr;83(4):470-8.
  7. Am J Cardiol. 2006 Feb 15;97(4):477-9.
  8. Arch Intern Med. 2002 Jul 22;162(14):1568-76.
  9. Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1783-9.
  10. JAMA. 2000 Sep 13;284(10):1263-70.
  11. Arch Intern Med. 2000 Apr 24;160(8):1177-84.
  12. Am J Cardiol. 2000 May 1;85(9):1100-5.
  13. Circulation. 1993 Jul;88(1):20-8.
  14. Am J Cardiol. 1998 Sep 15;82(6):737-43.
  15. JAMA. 1994 Mar 2;271(9):672-7.
  16. Neth J Med. 2004 Jul -Aug;62(7):229-34.
  17. J Clin Lipidol. 2012 Mar- Apr;6(2):121-31.
  18. Eur J Clin Pharmacol. 1991;40 Suppl 1:S49-S51.
  19. JAMA. 1990 Dec 19;264(23):3013-7.
  20. Am J Med. 2012 Oct;125(10):1026-35.
  21. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010 Jun 15;55(24):2721-67. [PMID: 20399059]
  22. Niacin. http://www.naturalstandard.com/naturalstandard/monographs/ monoframeset.asp?monograph=/monographs/herbssupplements/aux2-niacin. asp&patientVersion=/monographs/herbssupplements/patient-niacin. Accessed August 19, 2010.
  23. 23 Taylor AJ, Sullenberger LE, Lee HJ, et al. Biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004 Dec 7;110(23):3512-17. [PMID: 15537681]
  24. Duggal, JK; Singh, M; Attri, N; Singh, PP; Ahmed, N; Pahwa, S; Molnar, J; Singh, S et al. (2010). “Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease”. Journal of cardiovascular pharmacology and therapeutics 15 (2): 158–66.

Supplement Facts

Serving Size: 1 Capsule
Servings Per Container: 90
Amount Per Serving % Daily Value**
Niacin (Vitamin B-3) (as time released niacin) 250 mg 1250%
** Daily Values are based on a 2,000 calorie per day diet.

Suggested Use

Take 1 vegetarian capsule with a meal as a dietary supplement or as directed by a qualified health care professional.


If you are pregnant, nursing, or taking any medications, consult your doctor before use. Discontinue use and consult doctor if any adverse reactions occur.

Niacin 250 TR Label